Burden of Alzheimer's Disease–Related Mortality in the United States, 1999–2008

Moschetti, Kristin; Cummings, Patricia L.; Sorvillo, Frank; Kuo, Tony

doi:10.1111/j.1532-5415.2012.04056.x

Cited by 44 publications

(28 citation statements)

References 15 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moschetti et al 23 analyzed the time trend in mortality from Alzheimer's disease in the United States from 1999 to 2008 and found a 5% increase in the age-adjusted mortality rate, which was directly proportional to age. The oldest elderly showed systematically higher mortality rates.…”

Section: Discussionmentioning

confidence: 99%

Mortality from Alzheimer's disease in Brazil, 2000-2009

et al. 2015

View full text Add to dashboard Cite

Alzheimer's disease is the most prevalent type of dementia in the elderly worldwide. To evaluate the mortality trend from Alzheimer's disease in Brazil, a descriptive study was conducted with the Mortality Information System of the Brazilian Ministry of Health (2000-2009). Age and sex-standardized mortality rates were calculated in Brazil's state capitals, showing the percentage variation by exponential regression adjustment. The state capitals as a whole showed an annual growth in mortality rates in the 60 to 79 year age bracket of 8.4% in women and 7.7% in men. In the 80 and older age group, the increase was 15.5% in women and 14% in men. Meanwhile, the all-cause mortality rate declined in both elderly men and women. The increase in mortality from Alzheimer's disease occurred in the context of chronic diseases as a proxy for increasing prevalence of the disease in the population. The authors suggest healthcare strategies for individuals with chronic non-communicable diseases

show abstract

Section: Discussionmentioning

confidence: 99%

Mortality from Alzheimer's disease in Brazil, 2000-2009

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The worldwide direct costs of dementia care were estimated to be US$315 billion in 2005, increasing to US$422 billion in 2009 [Wimo et al, 2010], and exceeding US$604 billion in 2010 [Rosow et al, 2011]. In the United States, the costs were US$183 billion in 2011 [Moschetti et al, 2012], exceeding US$200 billion in 2012, and expected to top US$1.1 trillion by 2050 [Tejada-Vera, 2013]. As the world's population ages, with life expectancies anticipated to increase significantly, AD will inevitably impose an overbearing socioeconomic burden on our health systems unless an effective (preventive) therapeutic treatment is forthcoming [Selkoe, 2012;Mullane and Williams, 2013].…”

Section: Introductionmentioning

confidence: 98%

Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases

Irwin

Moos

Faller

et al. 2016

Drug Development Research

View full text Add to dashboard Cite

Preclinical Research In this review, we discuss epigenetic-driven methods for treating neurodegenerative disorders associated with mitochondrial dysfunction, focusing on carnitinoid antioxidant-histone deacetylase inhibitors that show an ability to reinvigorate synaptic plasticity and protect against neuromotor decline in vivo. Aging remains a major risk factor in patients who progress to dementia, a clinical syndrome typified by decreased mental capacity, including impairments in memory, language skills, and executive function. Energy metabolism and mitochondrial dysfunction are viewed as determinants in the aging process that may afford therapeutic targets for a host of disease conditions, the brain being primary in such thinking. Mitochondrial dysfunction is a core feature in the pathophysiology of both Alzheimer and Parkinson diseases and rare mitochondrial diseases. The potential of new therapies in this area extends to glaucoma and other ophthalmic disorders, migraine, Creutzfeldt-Jakob disease, post-traumatic stress disorder, systemic exertion intolerance disease, and chemotherapy-induced cognitive impairment. An emerging and hopefully more promising approach to addressing these hard-to-treat diseases leverages their sensitivity to activation of master regulators of antioxidant and cytoprotective genes, antioxidant response elements, and mitophagy. Drug Dev Res 77 : 109-123, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

“…Despite a lower prevalence and incidence rate, whites have a higher overall mortality rate from AD (Gillum & Obisesan, 2011;Mehta et al, 2008;Moschetti, Cummings, Sorvillo, & Kuo, 2012). In two recent studies, whites had dementia listed as the underlying or contributing cause of death on their death certificates slightly more often than blacks: from 1999 through 2004, the ageadjusted death rate per 100,000 was 64.7 for whites and 62.8 for blacks, a 3 percent difference (Gillum & Obisesan, 2011), and from 1999 through 2008, the age-adjusted mortality rate per 100,000 was 52.1 for whites, 44.3 for blacks, 32.3 for Hispanics, 26.8 for Native Americans, and 19.4 for Asians and Pacific Islanders (Moschetti et al, 2012). It should be noted that cause-of-death studies may be confounded by reporting bias, variations in diagnostic customs, and differences in access to diagnostic technologies.…”

Section: Health Outcomes and Symptom Burdenmentioning

confidence: 99%

Racial and Ethnic Disparities Among Individuals with Alzheimer’s Disease in the United States: A Literature Review

Lines¹,

Sherif²,

Wiener³

2014

115

View full text Add to dashboard Cite

This study reviews the published literature on racial and ethnic disparities among people with Alzheimer’s disease (AD) and related dementias in the United States. To identify relevant studies, we searched electronic sources for peer-reviewed journal articles and unpublished research reports that were published through July 2014; related to the AD population and their caregivers; and provided evidence of racial and ethnic disparities, discussed reasons for disparities, or described interventions to address disparities. The literature shows consistent and adverse disparities among blacks and Hispanics compared with non-Hispanic whites concerning AD, including the disease’s prevalence and incidence, mortality, participation in clinical trials, use of medications and other interventions, use of long-term services and supports, health care expenditures, quality of care, and caregiving. The literature suggests numerous underlying causes, including factors related to measurement of the disease, genetics, socioeconomic factors, cultural differences, lack of culturally competent clinicians, and discrimination. Although these disparities are well known, little is known about the effectiveness of various strategies, such as cultural competence training, to address these differences, and very few studies evaluate possible interventions.

show abstract

Burden of Alzheimer's Disease–Related Mortality in the United States, 1999–2008

Cited by 44 publications

References 15 publications

Mortality from Alzheimer's disease in Brazil, 2000-2009

Mortality from Alzheimer's disease in Brazil, 2000-2009

Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases

Racial and Ethnic Disparities Among Individuals with Alzheimer’s Disease in the United States: A Literature Review

Contact Info

Product

Resources

About